Trends in prescribing patterns of hormonal contraceptives for adolescents

Contraception

Volumn 77, Issue 4, 2008, Pages 264-269

  O'Brien, Sarah H ^a,b   Kaizar, Eloise E ^b   Gold, Melanie A ^c   Kelleher, Kelly J ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescence; Contraception; Deep venous thrombosis (DVT)

Indexed keywords

CONTRACEPTIVE AGENT; DESOGESTREL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS NORELGESTROMIN;

ADOLESCENT; ARTICLE; DATA ANALYSIS; DEMOGRAPHY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HORMONAL CONTRACEPTION; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; RISK; THROMBOSIS; UNITED STATES;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANDROSTENES; CHILD; CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; FEMALE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RISK FACTORS; UNITED STATES; VENOUS THROMBOSIS;

EID: 40649121471     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.12.009     Document Type: Article

References (26)

1. Gomes M.P., and Deitcher S.R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 164 (2004) 1965-1976
2. Petitti D.B. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 349 (2003) 1443-1450
3. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346 (1995) 1582-1588
4. Bloemenkamp K.W., Rosendaal F.R., Helmerhorst F.M., Buller H.R., and Vandenbroucke J.P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346 (1995) 1593-1596
5. Jick H., Jick S.S., Gurewich V., Myers M.W., and Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346 (1995) 1589-1593
6. de Jong-van den Berg L., Tobi H., Bijker B., and van den Berg P. Influence of the third generation pill controversy on prescriptions for oral contraceptives among first time users: population based study. BMJ 326 (2003) 254
7. Martin R.M., Hilton S.R., and Kerry S.M. The impact of the October 1995 'pill scare' on oral contraceptive use in the United Kingdom: analysis of a general practice automated database. Fam Pract 14 (1997) 279-284
8. National Center for Health Statistics. Ambulatory Health Care Data. Available at. http://www.cdc.gov/nchs/about/major/ahcd/ahcd1.htm Accessed June 22, 2007
9. Bloemenkamp K.W., Rosendaal F.R., Buller H.R., Helmerhorst F.M., Colly L.P., and Vandenbroucke J.P. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 159 (1999) 65-70
10. Lidegaard O., Edstrom B., and Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 65 (2002) 187-196
11. Hing E., Gousen S., Shimizu I., and Burt C. Guide to using masked design variables to estimate standard errors in public use files of the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. Inquiry 40 (2003) 401-415
12. Huber J., and Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception 73 (2006) 23-29
13. Nader S., and Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod 22 (2007) 317-322
14. Ortho Evra [full United States prescribing information] (2006), Ortho-McNeil Pharmaceutical, Inc, Raritan (NJ) [revised September]
15. Santelli J.S., Lindberg L.D., Finer L.B., and Singh S. Explaining recent declines in adolescent pregnancy in the United States: the contribution of abstinence and improved contraceptive use. Am J Public Health 97 (2007) 150-156
16. Tans G., Bouma B.N., Buller H.R., and Rosing J. Changes of hemostatic variables during oral contraceptive use. Semin Vasc Med 3 (2003) 61-68
17. Rosendaal F.R., Helmerhorst F.M., and Vandenbroucke J.P. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 22 (2002) 201-210
18. Kemmeren J.M., Algra A., and Grobbee D.E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 323 (2001) 131-134
19. Herings R.M., Urquhart J., and Leufkens H.G. Venous thromboembolism among new users of different oral contraceptives. Lancet 354 (1999) 127-128
20. Parkinson J, Park S, Wolfe SM, Rosendaal F. Petition to the FDA to ban third generation oral contraceptives containing desogestrel due to increased risk of venous thrombosis (Health Research Group Publication #1799). 2007. Available at http://www.citizen.org/publications/.
21. Archer D.F., Bigrigg A., Smallwood G.H., Shangold G.A., Creasy G.W., and Fisher A.C. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril 77 (2002) S27-S31
22. Cole J.A., Norman H., Doherty M., and Walker A.M. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 109 (2007) 339-346
23. Jick S.S., Kaye J.A., Russmann S., and Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 73 (2006) 223-228
24. Dinger J.C., Heinemann L.A., and Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75 (2007) 344-354
25. Farmer R.D., Lawrenson R.A., Thompson C.R., Kennedy J.G., and Hambleton I.R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 349 (1997) 83-88
26. Wilks J.F. Hormonal birth control and pregnancy: a comparative analysis of thromboembolic risk. Ann Pharmacother 37 (2003) 912-916